![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF445 |
Gene summary for ZNF445 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF445 | Gene ID | 353274 |
Gene name | zinc finger protein 445 | |
Gene Alias | ZFP445 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P59923 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
353274 | ZNF445 | HCC1_Meng | Human | Liver | HCC | 5.26e-51 | 7.60e-02 | 0.0246 |
353274 | ZNF445 | HCC2_Meng | Human | Liver | HCC | 2.03e-04 | -2.21e-02 | 0.0107 |
353274 | ZNF445 | HCC1 | Human | Liver | HCC | 1.93e-11 | 2.84e+00 | 0.5336 |
353274 | ZNF445 | HCC2 | Human | Liver | HCC | 9.57e-21 | 3.12e+00 | 0.5341 |
353274 | ZNF445 | HCC5 | Human | Liver | HCC | 6.16e-11 | 2.86e+00 | 0.4932 |
353274 | ZNF445 | S014 | Human | Liver | HCC | 3.78e-04 | 3.30e-01 | 0.2254 |
353274 | ZNF445 | S015 | Human | Liver | HCC | 9.35e-04 | 3.78e-01 | 0.2375 |
353274 | ZNF445 | S016 | Human | Liver | HCC | 2.28e-04 | 3.20e-01 | 0.2243 |
353274 | ZNF445 | S028 | Human | Liver | HCC | 5.29e-10 | 5.32e-01 | 0.2503 |
353274 | ZNF445 | S029 | Human | Liver | HCC | 1.86e-05 | 5.11e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF445 | SNV | Missense_Mutation | novel | c.908G>C | p.Gly303Ala | p.G303A | P59923 | protein_coding | tolerated(0.73) | benign(0) | TCGA-KU-A66T-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ZNF445 | SNV | Missense_Mutation | novel | c.2176N>T | p.Val726Phe | p.V726F | P59923 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-XJ-A83F-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD |
ZNF445 | SNV | Missense_Mutation | c.1883N>T | p.Thr628Ile | p.T628I | P59923 | protein_coding | tolerated(0.11) | benign(0) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
ZNF445 | SNV | Missense_Mutation | c.724N>T | p.Thr242Ser | p.T242S | P59923 | protein_coding | tolerated(0.31) | possibly_damaging(0.448) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | c.2985N>A | p.Ser995Arg | p.S995R | P59923 | protein_coding | tolerated(0.07) | benign(0.09) | TCGA-CG-4306-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | c.326G>C | p.Gly109Ala | p.G109A | P59923 | protein_coding | tolerated(0.21) | benign(0.077) | TCGA-CG-4437-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | rs146656660 | c.2089N>A | p.Val697Ile | p.V697I | P59923 | protein_coding | tolerated(1) | benign(0) | TCGA-HU-8602-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | xeloda | CR |
ZNF445 | SNV | Missense_Mutation | c.956N>G | p.Asn319Ser | p.N319S | P59923 | protein_coding | tolerated(0.79) | benign(0) | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | |
ZNF445 | SNV | Missense_Mutation | c.1669N>T | p.Arg557Cys | p.R557C | P59923 | protein_coding | deleterious(0.04) | benign(0.025) | TCGA-HU-A4H8-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | didox | PD | |
ZNF445 | SNV | Missense_Mutation | c.2413N>A | p.Leu805Ile | p.L805I | P59923 | protein_coding | deleterious(0.01) | benign(0.338) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |